publication date: Aug. 4, 2017

Conversation with The Cancer Letter

Charles Sawyers: Project GENIE demonstrates what a coalition of willing institutions is able to do

 

Charles Sawyers

Founder of Project GENIE, former president of AACR, and chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center

 

When former Vice President Joe Biden sought to convene and cajole cancer organizations into breaking down silos as part of the Cancer Moonshot, he frequently expressed frustration about reluctance on the part of cancer organizations to share data.

“You’re not going to like this, but imagine if you all worked together,” Biden said at the 2016 annual meeting of the American Society of Clinical Oncology. “I’m not joking! Imagine if you all worked together.” (The Cancer Letter, June 10, 2016).

Project GENIE, a publicly available genomic database run by the American Association for Cancer Research, is trying to meet Biden’s challenge, said Charles Sawyers, founder of Project GENIE, former president of AACR, and chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.

“I think the vice president was a little bit suspicious of our willingness to share data,” Sawyers said to The Cancer Letter. “I would say that we clearly overcame that.”

Project GENIE, short for the AACR Project Genomics Evidence Neoplasia Information Exchange, aggregates and links clinical cancer genomic data with clinical outcomes from patients treated at eight institutions.

“I think it’s a nice demonstration of what a coalition of … Continue reading Charles Sawyers: Project GENIE demonstrates what a coalition of willing institutions is able to do

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.